Novavax Inc. (NVAX)
Summary
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 164 | $1,040.16 | $1,380.06 | $339.9 | 32.68% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 7,400 | $49,356 | $62,271 | $12,915 | 26.17% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 130 | $4,737.85 | $1,079.65 | -$3,658.2 | -77.21% |
 Farallon Capital Farallon Capital Management LLC | 22,000 | $190,740 | $185,130 | -$5,610 | -2.94% |
| BG Bart Gancher Intech Investment Management LLC | 57,664 | $396,473.6 | $479,476.16 | $83,002.56 | 20.94% |
Novavax Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GZ George Zavoico B. Riley Securities | -68,522.05 | $337,813.69 | $577,640.86 | -$239,827.17 | -70.99% |
Novavax Inc. (NVAX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Novavax Inc. ever had a stock split?
Novavax Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Charles Jacobs CEO | NASDAQ (NGS) Exchange | 670002401 CUSIP |
| US Country | 749 Employees | 10 May 2019 Last Dividend | 10 May 2019 Last Split | 5 Dec 1995 IPO Date |
Overview
Novavax, Inc. is at the forefront of advancing public health through biotechnological innovation, focusing primarily on the development and commercialization of vaccines to counteract serious infectious diseases. Emphasizing an improved health agenda, the company leverages a unique vaccine platform that marries recombinant protein technology, cutting-edge nanoparticle science, and its proprietary Matrix-M adjuvant to amplify the body's immune response to pathogens. Targeting some of the most pressing health challenges of our time, including the ongoing battle against COVID-19 and influenza, Novavax is dedicated to providing effective vaccine solutions worldwide. Founded in 1987, it is headquartered in Gaithersburg, Maryland, marking over three decades of contributions to the field of biotechnology and public health.
Products and Services
Nuvaxovid/ Covovax/ Novavax COVID-19 Vaccine, Adjuvanted: This represents Novavax's premier commercialized product, the NVX-CoV2373 vaccine, which is available under various brand names such as Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted. Designed for the adult and adolescent populations, it serves as a primary series vaccine and is also applicable for homologous and heterologous booster shots. Building on the company's innovative approach, this vaccine aims to provide a robust defense against COVID-19, highlighting Novavax's commitment to combating the pandemic.
R21/Matrix-M Adjuvant Malaria Vaccine: Beyond its noteworthy contributions to the COVID-19 crisis, Novavax is also venturing into malaria, one of the most enduring public health challenges globally. The company is developing the R21/Matrix-M adjuvant malaria vaccine, a promising candidate that demonstrates Novavax's application of its technology and expertise beyond the realm of viral infections. This venture underscores the company's broader commitment to addressing urgent health challenges through innovative vaccine development.
